The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
The age of signing the informed consent is 18 -70 years, regardless of gender.
At least one measurable lesion according to RECIST v1.1 criteria.
The ECOG score is 0 or 1.
Expected survival ≥12 weeks.
Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases.
Spinal cord compression not cured by surgery and/or radiotherapy.
Subjects with uncontrolled tumor-related pain.
Received antitumor therapy within 4 weeks before the start of the study.